Sales of Biogen Idec's new multiple sclerosis drug Tecfidera fell short of Wall Street estimates for the first time. Its shares fell nearly 3 percent.» Read More
Amgen Inc. rose $1.55 or 1.1 percent, to $139.06. Biogen Idec rose $6.48 or 2.1 percent, to $317.89. Celgene Corp. rose $3.34 or 3.6 percent, to $95.34.
Amgen Inc. rose $3.82 or 2.9 percent, to $137.51. Biogen Idec rose $4.70 or 1.5 percent, to $311.41. Celgene Corp. rose $3.88 or 4.4 percent, to $92.00.
Amgen Inc. rose$. 35 or. 3 percent, to $134.04. Biogen Idec rose $3.41 or 1.1 percent, to $310.12. Celgene Corp. rose $3.24 or 3.7 percent, to $91.36.
Amgen Inc. rose$. 93 or. 7 percent, to $134.62. Biogen Idec rose $2.07 or. 7 percent, to $308.78. Celgene Corp. rose $1.72 or 2.0 percent, to $89.84.
Oct 16- Medical device and drug maker Baxter International Inc reported a higher-than-expected quarterly profit, as sales in its medical products business continued to grow. The company, whose profit topped expectations for the fourth straight quarter, cut its 2014 earnings forecast to $4.86- $4.89 per share to exclude gains from its vaccine business that it...
The first, Esbriet, was developed by InterMune Inc, which Switzerland- based Roche Holding AG agreed to buy for $8.3 billion in August, banking largely on the treatment's potential. The agency's decision marks a crucial milestone in the management of the disease, which affects about 100,000 people in the United States. Roche's drug, known generically as...
*Shire shares tumble as AbbVie reconsiders bid. NEW YORK, Oct 15- U.S. stocks dropped on Wednesday as economic data buttressed worries over the health of the world economy and signs emerged of slowing merger activity. Worries about a lethargic global economy weren't helped by data that showed U.S. retail sales and producer prices fell in September, while...
LONDON, Oct 8- A pioneering cannabis drug developed by British firm GW Pharmaceuticals for treating spasticity in multiple sclerosis has been rejected as not cost-effective in the company's home market. The National Institute for Health and Care Excellence, which determines if medicines are worth using on England's state health service, said on Wednesday...
If you’re looking for stock ideas, Cramer says thanks to good ol’ American ingenuity, this sector is bursting with them.
NEW YORK, Sept 24- Biotech stocks are moving higher on Wednesday, bouncing back from a two-day drop, helped by gains in Gilead Sciences after trial results for the company's HIV treatment.
Three biotech stocks have plenty of potential, John Schroer of Allianz Global Investors says.
Aug 27- Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.
Bankers and lawyers providing takeover advice said on Monday that Burger King Worldwide Inc's intention to move its tax domicile overseas through a so-called inversion deal- in this case the purchase of Canada's Tim Hortons- shouldn't be seen as a sign of a lot more deals to come.
Aug 21- Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.
Guess what delivers higher returns than both Google and Apple? (Hint: Think booze and underwear!)
Some of the names on the move ahead of the open.
Lance Slaughter from the ALS Association, discusses the phenomenon spreading across social media to dump a bucket of ice over your head to raise awareness for ALS.
CNBC's Meg Tirrell explains what ALS, or Lou Gehrig's disease is, and what is known about treating the disease.
Cramer often look inside the market for insights on broad sentiment. And certain things happened on Wednesday that suggest trouble.
U.S. stocks closed higher for the third time in four days as a rally in tech, airlines and biotech firms helped lead gains.